APEX Gesellschaft fuer angewandte Pharmakologie und experimentelle Pharmakotherapie mbH
- Address
- Landsberger Strasse 476, Pasing-Obermenzing, 81241 Munich, Germany
Immune System Diseases and Virus Diseases
The research at APEX Gesellschaft fuer angewandte Pharmakologie und experimentelle Pharmakotherapie mbH focuses on how the body handles antiviral and immune-related treatments, with an emphasis on renal impairment and its impact on treatment behavior. These studies are designed to better understand safety and effectiveness in people whose kidney function may alter how medicines are processed.
- Studying virus diseases with a focus on how kidney function affects antiviral therapy
- Exploring immune system diseases through research on medicine handling in adults with reduced kidney function
- Evaluating whether renal impairment changes how investigational treatments move through the body
Overall, the site’s trials aim to support better treatment planning by clarifying how kidney function may influence the performance of new therapies.
Renal Impairment Research in Pharmacology
This Munich-based laboratory and research facility is conducting focused clinical studies on renal impairment to assess how reduced kidney function affects the body’s response to candidate medicines. The work helps improve understanding of pharmacokinetics and supports safer use of treatments in patients with compromised kidney health.
- Assessing drug behavior in participants with normal and reduced kidney function
- Testing how renal impairment may change exposure to new therapies
- Supporting more informed dosing and treatment decisions for patients with kidney-related conditions
These studies contribute to broader clinical research in pharmacology by helping determine whether medicines can be used reliably across different levels of kidney function.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 162 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in APEX Gesellschaft fuer angewandte Pharmakologie und experimentelle Pharmakotherapie mbH
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Hepatic Impairment on Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) in Healthy Adult Participants | Janssen Cilag International | Phase I | Not Recruiting | Aug 2023 | Aug 2024 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Gs-5245 | 1 | Unknown | 2024-03-19 | 2024-03-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.